CD8+, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Somasundaram, Rajasekharan; Caputo, Laura; Guerry, DuPont; Herlyn, Dorothee

doi:10.1186/1479-5876-3-41

Journal of Translational Medicine

Table 2 Lysis of various HLA-matched and -unmatched target cells and IFN-γ secretion by CD8⁺ 793CTL

From: CD8⁺, HLA-unrestricted, cytotoxic T-lymphocyte line against malignant melanoma

Stimulator and target cell		HLA subtype^a	% Maximal	IFN-γ secretion	GM-CSF secretion
Designation	Origin	HLA subtype^a	Cyto-toxicity^b	(U/ml)^c	(U/ml)
WM793	Autologous primary melanoma	A1, A29, B57[17], B35, DRB1 11, DQB1 0301	40.1^d	10^d	5.1^d
1205LU^e	Autologous metastatic variant	A1, A29, B57[17], B35, DRB1 11, DQB1 0301	6.6	<0.01	<0.01
DM196	Allogeneic metastatic melanoma	A23(9), Aw34, B57[17], B44, DR1, DR3, DRw1, DRw52	12^d	2.2^d	2.5^d
ME9874	Allogeneic metastatic melanoma	A2, A24, B57[17], B60, Cw3, Cw7, DR7, DQ2	8.3^d	5.9^d	3.2^d
A375	Allogeneic metastatic melanoma	A1, A2, B57[17], C6	20.3^d	41.2^d	6.2^d
WM75	Allogeneic metastatic melanoma	A2, A29, B12w44, DR4, DR7	24.2^d	4.6^d	2.0^d
WM98	Allogeneic metastatic melanoma	A1, A3, B8, DR3	8.1	<0.01	<0.01
WM164	Allogeneic metastatic melanoma	A24, B7, C7, DR13, DQ1, DQ6, DRw52	29.8^d	1.6	2.0^d
WM1158	Allogeneic metastatic melanoma	A11, A24, B16, B60 (40), C3, DR13, DR4, DQ3, DQ6, DRw52, DRw53	45^d	<0.01	<0.01
U87MG	Allogeneic glioma	A2, B7, B44, Cw05, Cw07, DRB1 03, DRB115, DQB1 02, DQB1 06	0	<0.01	N.D.
U373MG	Allogeneic glioma	A2, B18, Cw05, DRB103	0	<0.01	N.D.
MDAMB231	Allogeneic breast carcinoma	A2, B40, B41, Cw02, Cw17, DRB1 07, DRB1 13, DQB1 02, DQB1 03	0	<0.01	N.D.
WC007	Allogeneic colorectal carcinoma	A1, A3, B35, DR1, DR4	0	<0.01	N.D.
WC008	Allogeneic colorectal carcinoma	A1, A3, B15,B57[17], DR4	0	<0.01	N.D.
FOM708	Allogeneic melanocytes	A1, A11, B7, B8, C1, C6	3.7	<0.01	<0.01
FOM723	Allogeneic melanocytes	A3, A29, B7, B44	7.8	<0.01	<0.01
FOM1020	Allogeneic melanocytes	A2, A3, B37, B57, C6	5.2	<0.01	<0.01
793 fibroblasts	Autologous fibroblasts	A1, A29, B57[17], B35, DRB1 11, DQB1 0301	N.D.^f	<0.01	N.D.
793 EBV-B	Autologous B cells	A1, A29, B57[17], B35, DRB1 11, DQB1 0301	0	1.3	N.D.
888EBV-B	Allogeneic B cells	A1, A24, B52, B55, C1, C7, DR15	N.D.	<0.01	N.D.
1363EBV-B	Allogeneic B cells	A1, A2, B44, B51, C1, DR1	N.D.	<0.01	N.D.
1088EBV-B	Allogeneic B cells	A1, A2, B8, B44, C5, DR4, DR17	N.D.	<0.01	N.D.
1102EBV-B	Allogeneic B cells	A2, A24, B55, B62, C3, DR4, DR15	N.D.	<0.01	N.D.
4226EBV-B	Allogeneic B cells	A24, A32, B27, B38, C3, DR4, DR15	N.D.	<0.01	N.D.
K562	NK-sensitive erythroleukemia cells	N.D.	0	<0.01	N.D.
Daudi	lymphokine-activated killer cell-sensitive lymphoma cells	N.D.	0	<0.01	N.D.

^a Based on tumor cell typing, except for WM75 and WM98 (based on lymphocyte typing). HLA types of WM793 cells and those matching between WM793 and other cells are in bold.
^b Lysis of labeled tumor target cells was determined in 4-hr ⁵¹Cr release assay using optimal E:T ratio of 20. Values represent means of triplicate determinations. Each cell line was tested in at least 2 different assays with similar results.
^c IFN-γ and GM-CSF secretions were determined by RIA. Values represent means of triplicate determinations. Each cell line was tested in at least 2 different assays with similar results.
^d p < 0.05 when compared to corresponding cpm values of spontaneous release of ⁵¹Cr by target cells and/or spontaneous release of cytokine by CTL.
^e Lung metastasis obtained in nude mice by injecting autologous WM793 cells s.c.[8]
^f N.D. = Not determined.

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com